Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Sarcoma 1Melanoma 1Lymphatic Metastasis 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 6Nivolumab 5cemiplimab 3Photochemotherapy 3Ipilimumab 3Vemurafenib 2Hsp90 inhibitor KU757 2tozuleristide 1toripalimab 1tislelizumab 1spartalizumab 1small molecule inhibitor THX-B 1poly ICLC 1montanide ISA 51 1liposomal doxorubicin 1durvalumab 1dostarlimab 1cobimetinib 1cc-486 1brodalumab 1avelumab 1atezolizumab 1Ultraviolet Rays 1Tumor Necrosis Factor-alpha 1Sunscreening Agents 1Sugars 1SUB1 protein, human 1Radiotherapy 1Propranolol 1Poly I-C 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Skin Neoplasms × Propranolol × Clear all
NCT05968690 2025-09-18

Naltrexone and Propranolol Combined With Immunotherapy

Rutgers, The State University of New Jersey

Phase 1 Recruiting
12 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡